Table 1 Genotype, tumour characteristics and endocrine therapy of the total study population (n = 226), including both oestrogen receptor (ER)-positive and ER-negative patients
From: Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
Characteristic | Genotype [n (%)] | |||||
|---|---|---|---|---|---|---|
CYP2D6*1/*1 | CYP2D6*1/*4 | CYP2D6*4/*4 | SULT1A1*1/*1 | SULT1A1*1/*2 | SULT1A1*2/*2 | |
Nodal involvementa, tumour size | ||||||
Node-, >30 mm | 19 (76.0) | 5 (20.0) | 1 (4.0) | 6 (24.0) | 11 (44.0) | 8 (32.0) |
Node+, ≤ 20 mm | 66 (74.2) | 18 (20.2) | 5 (5.6) | 30 (33.7) | 49 (55.1) | 10 (11.2) |
Node+, >20 mm | 77 (68.8) | 32 (28.6) | 3 (2.7) | 43 (38.4) | 59 (52.7) | 10 (8.9) |
Receptor statusb | ||||||
ER-negative | 50 (74.6) | 12 (17.9) | 5 (7.5) | 23 (34.3) | 35 (52.2) | 9 (13.4) |
ER-positive | 109 (69.9) | 43 (27.6) | 4 (2.6) | 56 (35.9) | 82 (52.6) | 18 (11.5) |
Endocrine therapy | ||||||
Tamoxifen | 77 (68.8) | 28 (25.0) | 7 (6.3) | 37 (33.0) | 60 (53.6) | 15 (13.4) |
No tamoxifen | 85 (74.6) | 27 (23.7) | 2 (1.8) | 42 (36.8) | 59 (51.8) | 13 (11.4) |